Literature DB >> 7912297

Generalised bone loss in patients with early rheumatoid arthritis.

A K Gough1, J Lilley, S Eyre, R L Holder, P Emery.   

Abstract

Generalised osteoporosis is a feature of established rheumatoid arthritis but whether this is a consequence of treatment, immobility, or disease activity has been unclear. We estimated bone mineral density by dual energy x-ray absorptiometry on 148 patients with early rheumatoid arthritis before treatment with corticosteroids or disease-modifying drugs and 730 normal controls. Scans were done at 12-month intervals in patients and at 0 and 12 months on 50 of the controls matched for menopausal status. At presentation, bone mineral density of patients did not differ from controls. However, patients with disease for less than 6 months had significantly higher spinal bone mineral density than those of longer duration. Over the next 12 months, bone mineral density loss was greater in patients with rheumatoid arthritis compared with controls; significantly so for early disease (eg, -2.4 [0.8] vs -0.6 [0.4] g/cm2, p < 0.05 in the spine and -4.3 [0.8] vs -0.4 [0.5] g/cm2, p < 0.001 in the trochanter). For the lumbar spine, only disease activity was significantly associated with this bone mineral density loss. For patients with active disease over 2 years, mean bone mineral density loss at each site was between 5.5 and 10% (p < 0.01 compared to patients with inactive disease). Suppression of disease activity stabilised this bone loss. In patients with rheumatoid arthritis significant amounts of generalised skeletal bone were lost early in the disease and the loss was associated with disease activity. These findings have implications for the management of patients with rheumatoid arthritis and possibly other inflammatory diseases.

Entities:  

Mesh:

Year:  1994        PMID: 7912297     DOI: 10.1016/s0140-6736(94)91049-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  170 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  P Boulos; G Ioannidis; J D Adachi
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 2.  Combination therapy in rheumatoid arthritis.

Authors:  S Bingham; P Emery
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis].

Authors:  G Hein; T Eidner; P Oelzner; B Manger
Journal:  Med Klin (Munich)       Date:  1999-10-15

4.  Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis.

Authors:  Gulsen Ozen; Diane L Kamen; Ted R Mikuls; Bryant R England; Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-11       Impact factor: 4.794

Review 5.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

6.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

7.  Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints.

Authors:  M Backhaus; G R Burmester; D Sandrock; D Loreck; D Hess; A Scholz; S Blind; B Hamm; M Bollow
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 8.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

9.  Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.

Authors:  Ho Jin Moon; Sung Eun Kim; Young Pil Yun; Yu Shik Hwang; Jae Beum Bang; Jae Hong Park; Il Keun Kwon
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

Review 10.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.